The DOI matches its Crossref record.
The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy
Abstract
Alterations in renal function and structure are found even at the onset of diabetes mellitus. Studies performed over the last decade now allow definition of a series of stages in the development of renal changes in diabetes. Such a classification may be useful both in clinical work and in research activities. Stage 1 is characterized by early hyperfunction and hypertrophy. These changes are found at diagnosis, before insulin treatment. Increased urinary albumin excretion, aggravated during physical exercise, is also a characteristic finding. Changes are at least partly reversible by insulin treatment. Stage 2 develops silently over many years and is characterized by morphologic lesions without signs of clinical disease. However, kidney function tests and morphometry on biopsy specimens reveal changes. The function is characterized by increased GFR. During good diabetes control, abumin excretion is normal; however, physical exercise unmasks changes in albuminuria not demonstrable in the resting situation. During poor diabetes control albumin excretion goes up both at rest and during exercise. A number of patients continue in stage 2 throughout their lives. Stage 3, incipient diabetic nephropathy, is the forerunner of overt diabetic nephropathy. Its main manifestation is abnormally elevated urinary albumin excretion, as measured by radioimmunoassay. A level higher than the values found in normal subjects but lower than in clinical disease is the main characteristic of this stage, which appeared to be between 15 and 300 μg/min in the baseline situation. A slow, gradual increase over the years is a prominent feature in this very decisive phase of renal disease in diabetes when blood pressure is rising. The increased rate in albumin excretion is higher in patients with increased blood pressure. GFR is still supranormal and antihypertensive treatment in this phase is under investigation, using the physical exercise test. Stage 4 is overt diabetic nephropathy, the classic entity characterized by persistent proteinuria (>0.5 g/ 24 h). When the associated high blood pressure is left untreated, renal function (GFR) declines, the mean fall rate being around 1 ml/min/mo. Long-term antihypertensive treatment reduces the fall rate by about 60%7 and thus postpones uremia considerably. Stage 5 is end-stage renal failure with uremia due to diabetic nephropathy. As many as 25% of the population presently entering the end-stage renal failure programs in the United States are diabetic. Diabetic nephropathy and diabetic vasculopathy constitute a major medical problem in society today.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Kramer, H. J. (2003) · JAMA · doi:10.1001/jama.289.24.3273 · Cited by 618
The tubular hypothesis of nephron filtration and diabetic kidney disease
Vallon, V., & Thomson, S. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0256-y · Cited by 465
Krop, J. S., Coresh, J., Chambless, L. E., Shahar, E., Watson, R. L., Szklo, M., & Brancati, F. L. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.15.1777 · Cited by 180
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy
Gordon, M. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(95)00420-3 · Cited by 125
Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay
Fiorentino, L., Cavalera, M., Menini, S., Marchetti, V., Mavilio, M., Fabrizi, M., Conserva, F., Casagrande, V., Menghini, R., Pontrelli, P., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201475 · Cited by 98
Insights into predicting diabetic nephropathy using urinary biomarkers
Khan, N. U., Lin, J., Liu, X., Li, H., Lu, W., Zhong, Z., Zhang, H., Waqas, M., & Shen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140475 · Cited by 90
Mangiferin prevents diabetic nephropathy progression in streptozotocin‐induced diabetic rats
Li, X., Cui, X., Sun, X., Li, X., Zhu, Q., & Li, W. (2010) · Phytotherapy Research · doi:10.1002/ptr.3045 · Cited by 91
The Stockholm Diabetes Intervention Study (SDIS): 18 months' results
REICHARD, P., BRITZ, A., CARS, I., NILSSON, B. Y., SOBOCINSKY‐OLSSON, B., & ROSENQVIST, U. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb16748.x · Cited by 71
Wang, Y., Yang, S., Zhou, Q., Zhang, H., & Yi, B. (2019) · Kidney and Blood Pressure Research · doi:10.1159/000498838 · Cited by 60
Diabetic nephropathy: Time to withhold development and progression - A review
Sharaf El Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.004 · Cited by 53
Meinhardt, U. (2003) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00180-0 · Cited by 38
Ma, H., He, K., Zhu, J., Li, X., & Ye, X. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.03.003 · Cited by 37
Zhu, Q., Zeng, J., Li, J., Chen, X., Miao, J., Jin, Q., & Chen, H. (2020) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2020/9817932 · Cited by 30
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
Metadata
- Authors
- Mogensen, C. E., Christensen, C. K., & Vittinghus, E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1983-06-01
- Volume
- 32
- Issue
- Supplement_2
- Pages
- 64-78
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2145027776
- Cited by
- 967
- References
- 0
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.